iTeos Therapeutics, Inc. (ITOS) Stock Analysis & Investment Frameworks
iTeos Therapeutics, Inc. (ITOS) stock analysis on Invetso. Review iTeos Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
iTeos Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
iTeos Therapeutics, Inc. Key Financial Metrics
- Market Cap: $448.68M
- Revenue: $35.00M
- ROE: -23.07%
- ROIC: -24.62%
- Dividend Yield: N/A
About iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
iTeos Therapeutics, Inc. Investment Frameworks
Invetso analyzes iTeos Therapeutics, Inc. (ITOS) across the following frameworks:
- iTeos Therapeutics, Inc. 10Y Growth Potential
- iTeos Therapeutics, Inc. Scenario Analysis
- iTeos Therapeutics, Inc. Risks & Opportunities
- iTeos Therapeutics, Inc. Economic Moat
- iTeos Therapeutics, Inc. Business Model
- iTeos Therapeutics, Inc. Management
- iTeos Therapeutics, Inc. SWOT Analysis
- iTeos Therapeutics, Inc. Porter's 5 Forces
- iTeos Therapeutics, Inc. PESTLE Analysis
- iTeos Therapeutics, Inc. ESG Analysis